105 related articles for article (PubMed ID: 30701264)
1. Combinatorial Efficacy of Quercitin and Nanoliposomal Ceramide for Acute Myeloid Leukemia.
McGill CM; Brown TJ; Fisher LN; Gustafson SJ; Dunlap KL; Beck AJ; Toran PT; Claxton DF; Barth BM
Int J Biopharm Sci; 2018; 1(1):. PubMed ID: 30701264
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Effect of Blueberry Extracts for Acute Myeloid Leukemia.
McGill CM; Brown TJ; Cheng YY; Fisher LN; Shanmugavelandy SS; Gustafson SJ; Dunlap KL; Lila MA; Kester M; Toran PT; Claxton DF; Barth BM
Int J Biopharm Sci; 2018 Jan; 1(1):. PubMed ID: 29607443
[TBL] [Abstract][Full Text] [Related]
3. Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation.
Barth BM; Keasey NR; Wang X; Shanmugavelandy SS; Rampal R; Hricik T; Cabot MC; Kester M; Wang HG; Shultz LD; Tallman MS; Levine RL; Loughran TP; Claxton DF
J Leuk (Los Angel); 2014 Sep; 2(3):. PubMed ID: 28239612
[TBL] [Abstract][Full Text] [Related]
4. Sphingolipid-mediated inflammatory signaling leading to autophagy inhibition converts erythropoiesis to myelopoiesis in human hematopoietic stem/progenitor cells.
Orsini M; Chateauvieux S; Rhim J; Gaigneaux A; Cheillan D; Christov C; Dicato M; Morceau F; Diederich M
Cell Death Differ; 2019 Sep; 26(9):1796-1812. PubMed ID: 30546074
[TBL] [Abstract][Full Text] [Related]
5. The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators.
Binder S; Luciano M; Horejs-Hoeck J
Cytokine Growth Factor Rev; 2018 Oct; 43():8-15. PubMed ID: 30181021
[TBL] [Abstract][Full Text] [Related]
6. Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia.
Ung J; Tan SF; Fox TE; Shaw JJP; Taori M; Horton BJ; Golla U; Sharma A; Szulc ZM; Wang HG; Chalfant CE; Cabot MC; Claxton DF; Loughran TP; Feith DJ
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136410
[TBL] [Abstract][Full Text] [Related]
7. Ceramide as a Target of Marine Triterpene Glycosides for Treatment of Human Myeloid Leukemia.
Yun SH; Shin SW; Stonik VA; Park JI
Mar Drugs; 2016 Nov; 14(11):. PubMed ID: 27827870
[TBL] [Abstract][Full Text] [Related]
8. Altered sphingomyelinase and ceramide expression in the setting of ischemic and nephrotoxic acute renal failure.
Zager RA; Conrad S; Lochhead K; Sweeney EA; Igarashi Y; Burkhart KM
Kidney Int; 1998 Mar; 53(3):573-82. PubMed ID: 9507201
[TBL] [Abstract][Full Text] [Related]
9. Neutral sphingomyelinase: past, present and future.
Chatterjee S
Chem Phys Lipids; 1999 Nov; 102(1-2):79-96. PubMed ID: 11001563
[TBL] [Abstract][Full Text] [Related]
10. Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen.
Morad SAF; MacDougall MR; Abdelmageed N; Kao LP; Feith DJ; Tan SF; Kester M; Loughran TP; Wang HG; Cabot MC
Exp Cell Res; 2019 Aug; 381(2):256-264. PubMed ID: 31112736
[TBL] [Abstract][Full Text] [Related]
11. Holotoxin A₁ Induces Apoptosis by Activating Acid Sphingomyelinase and Neutral Sphingomyelinase in K562 and Human Primary Leukemia Cells.
Yun SH; Sim EH; Han SH; Han JY; Kim SH; Silchenko AS; Stonik VA; Park JI
Mar Drugs; 2018 Apr; 16(4):. PubMed ID: 29642569
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
13. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
14. Acidic sphingomyelinase-generated ceramide is needed but not sufficient for TNF-induced apoptosis and nuclear factor-kappa B activation.
Higuchi M; Singh S; Jaffrezou JP; Aggarwal BB
J Immunol; 1996 Jul; 157(1):297-304. PubMed ID: 8683130
[TBL] [Abstract][Full Text] [Related]
15. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
Xu L; Zhang Y; Gao M; Wang G; Fu Y
Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
[TBL] [Abstract][Full Text] [Related]
16. Estrogen Receptors Alpha and Beta in Acute Myeloid Leukemia.
Roma A; Spagnuolo PA
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32276421
[TBL] [Abstract][Full Text] [Related]
17. Bcl-xL interrupts oxidative activation of neutral sphingomyelinase.
Okamoto Y; Obeid LM; Hannun YA
FEBS Lett; 2002 Oct; 530(1-3):104-8. PubMed ID: 12387875
[TBL] [Abstract][Full Text] [Related]
18. The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
Muñoz M; Coveñas R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492831
[TBL] [Abstract][Full Text] [Related]
19. The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.
Tan SF; Pearson JM; Feith DJ; Loughran TP
Expert Opin Ther Targets; 2017 Jun; 21(6):583-590. PubMed ID: 28434262
[TBL] [Abstract][Full Text] [Related]
20. Extracts of Devil's club (Oplopanax horridus) exert therapeutic efficacy in experimental models of acute myeloid leukemia.
McGill CM; Alba-Rodriguez EJ; Li S; Benson CJ; Ondrasik RM; Fisher LN; Claxton DF; Barth BM
Phytother Res; 2014 Sep; 28(9):1308-14. PubMed ID: 25340187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
